ストックスクリーナーアプリを入手
34.14
5.11%
1.66
前日終値:
$32.48
開ける：
$33.58
24時間の取引高:
3.49M
Relative Volume:
1.66
時価総額：
$3.51B
収益：
$164.01M
当期純損益:
$-65.04M
株価収益率:
-49.69
EPS:
-0.687
ネットキャッシュフロー:
$-383.84M
1週間 パフォーマンス:
+16.08%
1か月 パフォーマンス:
+27.34%
6か月 パフォーマンス:
+30.45%
1年 パフォーマンス:
+100.94%
1日の値動き範囲:
$32.66
$34.35
1週間の範囲:
$28.67
$34.35
52週間の値動き範囲:
$15.60
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
34.14 | 3.51B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - Zacks Investment Research
Beam Therapeutics stock soars 21% in three months: Here's why - MSN
Beam Therapeutics (BEAM) Receives FDA Approval for BEAM-304 IND Application - GuruFocus
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial - Stock Titan
Beam Therapeutics gets FDA clearance for BEAM-304 - grafa.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial - Investing.com
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beam Therapeutics Inc (BEAM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beam Therapeutics Inc (BEAM) Institutional Confidence - TradingKey
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why - The Globe and Mail
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts? - Yahoo Finance
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
BEAM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Precision Trading with Beam Therapeutics Inc. (BEAM) Risk Zones - Stock Traders Daily
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Amova Asset Management Americas Inc. Cuts Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Geode Capital Management LLC Sells 39,035 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (Nasdaq: BEAM) shareholders approve directors, auditor and pay - Stock Titan
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Beam Therapeutics (BEAM) director receives 19,676-share option grant - Stock Titan
Beam Therapeutics (BEAM) director receives stock options grant for 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) grants 19,676 stock options to director - Stock Titan
Beam Therapeutics (BEAM) director receives stock options on 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) awards stock options to director Chirfi - Stock Titan
Beam Therapeutics (BEAM) awards director Graham Cooper 19,676 options - Stock Titan
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 10.1% HigherWhat's Next? - MarketBeat
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
BEAM Technical Analysis & Stock Price Forecast - Intellectia AI
Beam Therapeutics Stock Hits Day Low of $28.80 Amid Price Pressure - Markets Mojo
Beam Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Technical Reactions to BEAM Trends in Macro Strategies - Stock Traders Daily
Draft FDA guidance could be a boon for gene therapy developers - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - AOL.com
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD - Yahoo Finance
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):